Biocon wins US FDA approval for cancer biosimilar Pebrilzo, strengthening its oncology portfolio ahead of a 2028 launch; learn more.
Leading pharma companies like Cipla, Dr Reddy’s, Glenmark, and Sun Pharma rely on key product launches in respiratory, peptide, and…
The NPPA urges strict monitoring of revised prices for 137 anti-cancer drugs to ensure hospitals, pharmacies, and distributors comply, aiming…
Only 5 of 16 states and UTs have completed onboarding on the CDSCO SUGAM Labs portal, which tracks medicine quality…
Revised prices for 1,364 anti-cancer drug formulations take effect, capping trade margins at 30%, saving patients Rs 3,540.38 crore annually…
The reports on medical device adverse events (MDAEs) reveal broad figures without detailed categorization of serious cases, with many minor…
Lupin’s Q2 net profit fell 18% QoQ to Rs 1,115 crore as competition hit key products, while sales rose 14%…
Piramal Pharma returned to profit in Q2 FY27 but reported a loss for H1. The company raised FY27 revenue growth…
India’s CRDMO sector is approaching a crucial growth phase as fresh manufacturing capacity and customer-backed projects prepare to drive revenue.…
Cipla Q2FY27 profit fell 35% YoY to Rs 877.54 crore as product revenue slipped, while shares declined intraday; read the…
About 17% of Indian drug factories inspected by the USFDA faced serious regulatory issues, risking delays in approvals and sales;…
Nifty 50 falls 2.3% as India VIX rises. Check key support levels, FII positioning and technical outlook for Realty, Pharma…
Patients buying cancer medicines may face limited relief as the government’s price control allows annual price increases. NPPA caps margins…
Cancer drug margin caps may cut hospital EBITDA by 1.5-3%, while lowering patient costs from Nov. 9; see what changes…
Mankind Pharma to acquire 70% stake in Belgium-based Armed Cell Therapeutics B.V. for EUR 48 million, marking its entry into…
The Supreme Court questioned the government on limiting a 30% trade margin cap to cancer drugs, raising concerns over high…
Sunil Singhania’s fund has crossed the 1% mark in a chemical maker that supplies Baker Hughes and Saudi Aramco. Madhusudan…
Both stocks have grown profit for five quarters in a row, and both have multiplied in a year. One is…